



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 November 2011
EMA/CHMP/651318/2011
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Nevanac nepafenac

On 17 November 2011, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Nevanac. The marketing authorisation holder for this medicinal product is Alcon Laboratories (UK) Ltd. They may request a re examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a new indication as follows:

"reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients".

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indications for Nevanac will be as follows²:

- Prevention and treatment of postoperative pain and inflammation associated with cataract surgery
- **Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.**
(see section 5.1)

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion.

² The text in bold represents the new or the amended indication.

